このエピソードについて

英語
アメリカ合衆国

文字起こし 🔗

過去のエピソードを検索

ASH 2014の以前のエピソードを検索します。

このポッドキャストの他のエピソード

Prof Marivi Mateos of the University Hospital of Salamanca, Salamanca, Spain speaks to ecancertv at ASH 2014 about the results of a phase I study on the use of daratumumab, an anti-CD38 antibody, in combination with standard approaches to treat relapsed multiple myeloma.
Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA talks to ecancertv at ASH 2014 about the use of T cell therapy for children with aggressive leukaemia.
Prof Burnett (Head of Haematology Department of Medical Genetics, Cardiff, Wales) and Prof Amadori (Tor Vergata University Hospital, Rome, Italy) review the data and opinions arising from ASH 2014 about the treatment of acute myeloid leukaemia (AML) for ecancertv. They debate the use of intensifie…
Prof Keith Stewart of the Mayo Clinic, Scottsdale, USA talks to ecancertv at ASH 2014 about the phase III ASPIRE study looking at the use of carfilzomib in multiple myeloma. “By adding carfilzomib to the gold standard in multiple myeloma therapy, we are observing an unprecedented duration of remis…
Prof Gribben (Queen Mary University London, London, UK) and Prof Stilgenbauer (Universitätsklinikum Ulm, Ulm, Germany) review the data and opinions arising from ASH 2014 about the treatment of chronic lymphocytic leukaemia (CLL) for ecancertv. The experts offer a comprehensive analysis of the curr…
免責: このページに埋め込まれているポッドキャストとアートワークは ecancertv からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。